Sravathi AI–Mayo Clinic Collaboration Receives Recognition Across Leading Media and Industry Platforms
Sravathi AI’s collaboration with Mayo Clinic on the development of a cancer drug candidate targeting GIPC1 has received recognition across leading media and industry platforms.
The collaboration focuses on GIPC1, a historically challenging and difficult-to-drug cancer target, and represents an important milestone in Sravathi AI’s efforts to apply artificial intelligence to complex challenges in drug discovery.
The work has been featured across a range of prominent healthcare, pharmaceutical, technology, and mainstream media platforms, including The Times of India, The Indian Express, Digital Health News, NewsBytes, ETV Bharat, ET Pharma, and Mayo Clinic News Network.
The coverage highlights the scientific and technological approach behind the collaboration, as well as the potential of AI-enabled drug discovery to address challenging biological targets and accelerate the development of potential new medicines.
For Sravathi AI, the recognition reflects the strength of the collaboration with Mayo Clinic and the collective efforts of the scientific, clinical, and technology teams working to advance this programme.
We are proud of the work accomplished through this collaboration and look forward to building on this progress as we continue to explore new possibilities at the intersection of AI, biology, and drug discovery.
Read more about the collaboration and the research.
